{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:29:00Z","timestamp":1761362940222,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jcv.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T13:35:12Z","timestamp":1567517712000},"page":"12-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy"],"prefix":"10.1016","volume":"120","author":[{"given":"Michael L.","family":"Spinner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-1873","authenticated-orcid":false,"given":"Simon W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Koval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-8411","authenticated-orcid":false,"given":"Vasilios","family":"Athans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2019.09.001_bib0005","series-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases","first-page":"1738","article-title":"Cytomegalovirus (CMV) [chapter 140]","author":"Crumpacker","year":"2015"},{"issue":"6","key":"10.1016\/j.jcv.2019.09.001_bib0010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jcv.2019.09.001_bib0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archinte.1979.03630400011006","article-title":"Cytomegalovirus: the troll of transplantation","volume":"139","author":"Balfour","year":"1979","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.jcv.2019.09.001_bib0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0163-4453(92)93417-O","article-title":"Foscarnet and ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison","volume":"25","author":"Moyle","year":"1992","journal-title":"J. Infect."},{"issue":"10","key":"10.1016\/j.jcv.2019.09.001_bib0025","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jcv.2019.09.001_bib0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00561-13","article-title":"Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens","volume":"58","author":"Minces","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jcv.2019.09.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12852","article-title":"Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study","volume":"20","author":"Pierce","year":"2017","journal-title":"Transpl. Infect. Dis."},{"year":"2018","series-title":"Foscarnet Sodium Injection [package Insert]","key":"10.1016\/j.jcv.2019.09.001_bib0040"},{"key":"10.1016\/j.jcv.2019.09.001_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.jcv.2019.09.001_bib0050","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00042560-199904010-00005","article-title":"Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations","volume":"20","author":"Aweeka","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"issue":"1","key":"10.1016\/j.jcv.2019.09.001_bib0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.jcv.2019.09.001_bib0060","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1128\/AAC.36.9.1821","article-title":"Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients","volume":"36","author":"Taburet","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2019.09.001_bib0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/archopht.1996.01100130021004","volume":"114","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jcv.2019.09.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1177\/1060028019860515","article-title":"Expanding beyond vancomycin and aminoglycosides: a novel pharmacist-managed dosing service","author":"Pillinger","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.jcv.2019.09.001_bib0075","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/ndt\/10.6.882","article-title":"Reversible acute renal failure caused by the combined use of foscarnet and cyclosporine in organ transplanted patients","volume":"10","author":"Morales","year":"1995","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.jcv.2019.09.001_bib0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1998","journal-title":"Am. J. Nephrol."},{"issue":"7","key":"10.1016\/j.jcv.2019.09.001_bib0085","first-page":"941","article-title":"A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet","volume":"7","author":"Siedel","year":"1993","journal-title":"AIDS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219301969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219301969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:12:37Z","timestamp":1761361957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653219301969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":17,"alternative-id":["S1386653219301969"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2019.09.001","relation":{},"ISSN":["1386-6532"],"issn-type":[{"type":"print","value":"1386-6532"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}